Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Desloratadine - Merck & Co

Drug Profile

Desloratadine - Merck & Co

Alternative Names: Aerius; Allex; Azomyr; Clarinex; Clarinex Reditabs; Clarinex-D 12 Hour; DCL; Decarboethoxyloratadine; Desalex; Descarboethoxyloratadine; Di Heng Sai; MK-4117; Neoclarityn; Opulis; SCH-34117

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sepracor
  • Developer Merck & Co
  • Class Antiallergics; Dibenzocycloheptenes; Nonsedating antihistamines; Piperidines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atopic dermatitis; Chronic urticaria; Dermatitis; Perennial allergic rhinitis; Pruritus; Seasonal allergic rhinitis
  • Discontinued Asthma

Most Recent Events

  • 01 Mar 2022 Launched for Chronic-urticaria in Iceland (PO) prior to March 2022
  • 01 Mar 2022 Launched for Seasonal allergic rhinitis in Iceland (PO) prior to March 2022
  • 04 Jul 2019 Desloratadine is not yet available for Chronic-urticaria in Iceland and Liechtenstein
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top